Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults
Status:
Active, not recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
This Phase 2/3 study is a multi-portion design to confirm that the chosen formulation and
dosing regimen of CoVLP has an acceptable immunogenicity and safety profile.
The Phase 3 portion is an event-driven, randomized, observer blinded, placebo-controlled
design that will evaluate the efficacy and safety of the CoVLP formulation compared to
placebo.
Subjects will be followed for safety and immunogenicity for a period of 12 months after the
last vaccination.